Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.680
+0.050 (3.07%)
At close: Mar 27, 2026, 4:00 PM EDT
1.720
+0.040 (2.38%)
After-hours: Mar 27, 2026, 7:03 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $221.81 million as of March 27, 2026. Its market cap has increased by 9.38% in one year.
Market Cap
221.81M
Enterprise Value
43.05M
1-Year Change
9.38%
Ranking
Category
Stock Price
$1.68
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $221.81M, an increase of 120.81%. That is a compound annual growth rate of 16.25%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 286.31M | 2.11% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Agenus | 131.71M |
| Equillium | 130.88M |
| Oramed Pharmaceuticals | 129.76M |
| AN2 Therapeutics | 129.75M |
| Artiva Biotherapeutics | 129.27M |
| ProMIS Neurosciences | 126.89M |
| Black Diamond Therapeutics | 122.60M |
| Innate Pharma | 118.09M |